Trials / Completed
CompletedNCT04671615
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.
DEMOGRAPHICS, PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS TREATED WITH PALBOCICLIB IN A REAL LIFE SETTING IN ISRAEL
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 559 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to understand the treatment patterns, patients and their clinical outcomes in a real life setting in Israel. This study was done in adult breast cancer patients who have started palbociclib combination treatment as per the national basket of health services in January 2018 until August 2020 for all lines of therapy. This study had included adult patients who were prescribed with palbociclib for their breast cancer which had spread to other parts of the body. Patients are followed for around 3.5 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | palbociclib | As provided in real world practice |
Timeline
- Start date
- 2020-12-06
- Primary completion
- 2022-11-30
- Completion
- 2022-11-30
- First posted
- 2020-12-17
- Last updated
- 2025-12-10
- Results posted
- 2023-08-18
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT04671615. Inclusion in this directory is not an endorsement.